Watch SYN2BIO SPÓŁKA AKCYJNA for free: we tell you when fair value or trend changes.

SYN2BIO SPÓŁKA AKCYJNA (S2B) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of SYN2BIO SPÓŁKA AKCYJNA stock PLN 31.03, price PLN 61.96, that is 49.9% below the price, quality 44 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

EstimateBear 23.27 PLN to bull 38.79 PLN Growth analysisrevenue history, year by year Quality 44/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLSNBIO00013

Thin data Nov 10, 2026

SYN2BIO SPÓŁKA AKCYJNA

S2B · WAR

Weakest Setup

Our calculation puts a fair price 50% below what the stock costs today.

Low debt

Ranks above peers (5/8)

Quality 44/100

Fair value 31.03 PLN · Strongly overvalued

Negative free cash flow

Narrow moat 23/100 · thin data

Thin data

Estimate

Watch SYN2BIO SPÓŁKA AKCYJNA for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

7‑month range 26.70 PLN – 82.26 PLN · fair‑value band 23.27 PLN – 38.79 PLN · the 61.96 PLN price screens above the 31.03 PLN fair value. As of Nov 10, 2026.

Follow SYN2BIO SPÓŁKA AKCYJNA in your weekly email

Every Wednesday you see whether SYN2BIO SPÓŁKA AKCYJNA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Syn2bio S.A., a biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion.

Show moreShow less

The company's flagship project is the cardiotracer project, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease.

Additionally, it operates The Centre for Research on New Compounds, a unit engaged in the search for new pharmaceutical compounds and their further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.

Stock analysis

SYN2BIO SPÓŁKA AKCYJNA (S2B) currently trades at 61.96 PLN, while our estimate is 31.03 PLN, 50% below the price, so the stock looks overvalued today.

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 23.27 PLN (bear) to 38.79 PLN (bull), the price of 61.96 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

SYN2BIO SPÓŁKA AKCYJNA reported revenue of 0 PLN in FY2025 versus 0 PLN in FY2023. Reported net income was −23.7M PLN in FY2025.

Key figures

Market cap 541M PLN (≈ $138M) Micro · EPS (TTM) −2.87 PLN · Return on assets (EBIT) −103% (3-year average) · Free cash flow −21.1M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −50%, S2B screens richer than that median.

Fair Value

Bear 23.27 PLN Fair Value 31.03 PLN Bull 38.79 PLN

Price 61.96 PLN · Downside -49.9%

Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0

How much profit the company makes from its sales and capital

Quality Growth 25

Are margins and returns getting better?

Cashflow 24

Do the profits arrive as real cash?

Financial strength 97

Debt, balance sheet and risk of trouble

Low Volatility 0

How calm the share price moves, does not count

Price momentum 71

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 100

Distance to the 52-week high, does not count

New shares 82

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required

not computed

S2B screens overvalued: fair value 50% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare SYN2BIO SPÓŁKA AKCYJNA with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/6 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 44 · Above median

Fair Value upside −49.9% · Bottom 25%

Profitability

Return on assets −90.3% · Bottom 25%

Operating margin (12 months) 0.0% · Above median

Growth and dividend

Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.29× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)0 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Regeneron Pharmaceuticals, Inc REGN	$916.06	$1,275	+39%	vs S2B
Samsung Biologics Co 207940	1,468,000 KRW	1,661,000 KRW	+13%	vs S2B
Vertex Pharmaceuticals Incorporated VRTX	$547.89	$601.80	+10%	vs S2B
Genmab A/S GMAB	kr 3,581	kr 3,880	+8%	vs S2B
argenx SE ARGX	$971.55	$908.40	−7%	vs S2B
CSL Limited CSL	A$201.68	A$181.40	−10%	vs S2B
Moderna, Inc MRNA	$250.83	$158.70	−37%	vs S2B
BeOne Medicines AG 6160	HK$252.20	HK$152.80	−39%	vs S2B
Celltrion, Inc 068270	203,000 KRW	74,945 KRW	−63%	vs S2B
Royalty Pharma plc RPRX	$69.45	$19.01	−73%	vs S2B

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks Stocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SYN2BIO SPÓŁKA AKCYJNA: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/S2B?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/S2B.WAR.svg" width="360" height="84" alt="SYN2BIO SPÓŁKA AKCYJNA: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "SYN2BIO SPÓŁKA AKCYJNA Fair Value". https://www.fairvalue-calculator.com/stock/S2B

Frequently asked questions

Is SYN2BIO SPÓŁKA AKCYJNA (S2B) overvalued or undervalued?

As of Nov 10, 2026, our estimate of fair value is 31.03 PLN versus a price of 61.96 PLN, about 50% lower (overvalued).

What is the fair value of S2B?

Our estimate for SYN2BIO SPÓŁKA AKCYJNA is 31.03 PLN (as of Nov 10, 2026), built from audited fundamentals. The current price: 61.96 PLN.

What is the quality score of S2B?

SYN2BIO SPÓŁKA AKCYJNA has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for SYN2BIO SPÓŁKA AKCYJNA (S2B)?

Our calculated price target is the estimate of 31.03 PLN (as of Nov 10, 2026). Cautious scenario 23.27 PLN, optimistic scenario 38.79 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.

What is the SYN2BIO SPÓŁKA AKCYJNA stock forecast for 2026?

Our estimate puts fair value at 31.03 PLN, about 50% lower versus a price of 61.96 PLN (overvalued). Cautious scenario 23.27 PLN, optimistic scenario 38.79 PLN. The calculation is refreshed regularly with new filings.

What is the intrinsic value of SYN2BIO SPÓŁKA AKCYJNA (S2B)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SYN2BIO SPÓŁKA AKCYJNA it is 31.03 PLN per share (as of Nov 10, 2026), against a price of 61.96 PLN.

Is SYN2BIO SPÓŁKA AKCYJNA stock overvalued or undervalued in 2026?

As of Nov 10, 2026, S2B trades above its calculated fair value: price 61.96 PLN, fair value 31.03 PLN, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of S2B?

No. The price is what the market pays today (61.96 PLN); the fair value is what the company's own numbers justify (31.03 PLN). For SYN2BIO SPÓŁKA AKCYJNA the two are 30.93 PLN per share apart. That gap is exactly why we show both numbers side by side.

How much is SYN2BIO SPÓŁKA AKCYJNA worth?

The market values SYN2BIO SPÓŁKA AKCYJNA at about 541M PLN (market capitalisation, as of Nov 10, 2026). Per share that is 61.96 PLN; our models calculate a fair value of 31.03 PLN per share.

What do the bullish and bearish scenarios say about S2B?

Our models span a range for SYN2BIO SPÓŁKA AKCYJNA: cautious scenario 23.27 PLN, base 31.03 PLN, optimistic 38.79 PLN per share (as of Nov 10, 2026, price 61.96 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.

Which stocks are comparable to SYN2BIO SPÓŁKA AKCYJNA?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is SYN2BIO SPÓŁKA AKCYJNA stock attractive at the current price?

The data as of Nov 10, 2026: price 61.96 PLN, calculated fair value 31.03 PLN (−50%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

Is it still worth investing in stocks now?

The global stock market currently sits 15.1% above its aggregate fair value. SYN2BIO SPÓŁKA AKCYJNA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of SYN2BIO SPÓŁKA AKCYJNA (S2B)?

The closing price on Nov 10, 2026 was 61.96 PLN. Our estimate is 31.03 PLN, about 50% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with SYN2BIO SPÓŁKA AKCYJNA right now?

The price sits above even our optimistic bull case (38.79 PLN). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of SYN2BIO SPÓŁKA AKCYJNA

How large is the market capitalisation of SYN2BIO SPÓŁKA AKCYJNA (S2B)?

The market capitalisation of SYN2BIO SPÓŁKA AKCYJNA is 541M PLN (≈ $138M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of SYN2BIO SPÓŁKA AKCYJNA (S2B)?

Earnings per share at SYN2BIO SPÓŁKA AKCYJNA are −2.87 PLN. Earnings per share over the last twelve months: total profit spread across every single share.

What is the EBIT return on assets of SYN2BIO SPÓŁKA AKCYJNA (S2B)?

On an EBIT basis the return on assets of SYN2BIO SPÓŁKA AKCYJNA is −103% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How much free cash flow does SYN2BIO SPÓŁKA AKCYJNA (S2B) generate?

The free cash flow of SYN2BIO SPÓŁKA AKCYJNA is −21.1M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

Free · no account needed

Watch SYN2BIO SPÓŁKA AKCYJNA in the live analysis

One click puts SYN2BIO SPÓŁKA AKCYJNA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.